Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Green Cross Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Green Cross Corporation - Product Pipeline Review - 2016', provides an overview of the Green Cross Corporation's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Green Cross Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Green Cross Corporation - The report provides overview of Green Cross Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Green Cross Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Green Cross Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Green Cross Corporation's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Green Cross Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Green Cross Corporation's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Green Cross Corporation Snapshot 6 Green Cross Corporation Overview 6 Key Information 6 Key Facts 6 Green Cross Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 Green Cross Corporation - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Green Cross Corporation - Pipeline Products Glance 14 Green Cross Corporation - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Green Cross Corporation - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Green Cross Corporation - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Green Cross Corporation - Drug Profiles 20 immune globulin (human) 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 antihemophilic factor (recombinant) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 GC-1107 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 GC-3106A 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 idursulfase beta 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 margetuximab 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 GC-1102 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 GC-1109 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 GC-1118A 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 GC-3111A 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 GCC-2107 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 MG-1111 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Monoclonal Antibody Conjugate to Target HER2 for Breast Cancer 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 LCB-141XXX 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Green Cross Corporation - Pipeline Analysis 36 Green Cross Corporation - Pipeline Products by Target 36 Green Cross Corporation - Pipeline Products by Route of Administration 38 Green Cross Corporation - Pipeline Products by Molecule Type 39 Green Cross Corporation - Pipeline Products by Mechanism of Action 40 Green Cross Corporation - Recent Pipeline Updates 41 Green Cross Corporation - Dormant Projects 45 Green Cross Corporation - Company Statement 46 Green Cross Corporation - Locations And Subsidiaries 47 Head Office 47 Other Locations & Subsidiaries 47 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Green Cross Corporation, Key Information 6 Green Cross Corporation, Key Facts 6 Green Cross Corporation - Pipeline by Indication, 2016 8 Green Cross Corporation - Pipeline by Stage of Development, 2016 10 Green Cross Corporation - Monotherapy Products in Pipeline, 2016 11 Green Cross Corporation - Partnered Products in Pipeline, 2016 12 Green Cross Corporation - Partnered Products/ Combination Treatment Modalities, 2016 13 Green Cross Corporation - Pre-Registration, 2016 14 Green Cross Corporation - Phase III, 2016 15 Green Cross Corporation - Phase II, 2016 16 Green Cross Corporation - Phase I, 2016 17 Green Cross Corporation - Preclinical, 2016 18 Green Cross Corporation - Discovery, 2016 19 Green Cross Corporation - Pipeline by Target, 2016 37 Green Cross Corporation - Pipeline by Route of Administration, 2016 38 Green Cross Corporation - Pipeline by Molecule Type, 2016 39 Green Cross Corporation - Pipeline Products by Mechanism of Action, 2016 40 Green Cross Corporation - Recent Pipeline Updates, 2016 41 Green Cross Corporation - Dormant Developmental Projects,2016 45 Green Cross Corporation, Other Locations 47 Green Cross Corporation, Subsidiaries 48
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.